A stock offering by Trius Therapeutics is bringing in $34.1 million to fund research and development and other corporate expenses. Tedizolid phosphate, the firm's lead product, is being tested against severe infections such as methicillin-resistant Staphylococcus aureus.
Antibiotic company Trius secures funding for R&D
SmartBrief Job Listings for Health Care
|Junior to Mid-Level FDA Associate||
|Global Counsel - Advertising and Promotions||
|Associate Director, Compliance & Ethics, US Operations Ops II||
|Senior Associate, Health Economics - Heart Valve Therapy||
|Health Economics & Reimbursement Manager - Transcatheter Heart Valve||